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Abstract
Background: Based on clinical representation of disease symptoms multiple sclerosis (MScl) patients can be divided into
two major subtypes; relapsing remitting (RR) MScl (85–90%) and primary progressive (PP) MScl (10–15%). Proteomics
analysis of cerebrospinal fluid (CSF) has detected a number of proteins that were elevated in MScl patients. Here we
specifically aimed to differentiate between the PP and RR subtypes of MScl by comparing CSF proteins.
Methodology/Principal Findings: CSF samples (n=31) were handled according to the same protocol for quantitative mass
spectrometry measurements we reported previously. In the comparison of PP MScl versus RR MScl we observed a number
of differentially abundant proteins, such as protein jagged-1 and vitamin D-binding protein. Protein jagged-1 was over three
times less abundant in PP MScl compared to RR MScl. Vitamin D-binding protein was only detected in the RR MScl samples.
These two proteins were validated by independent techniques (western blot and ELISA) as differentially abundant in the
comparison between both MScl types.
Conclusions/Significance: The main finding of this comparative study is the observation that the proteome profiles of CSF
in PP and RR MScl patients overlap to a large extent. Still, a number of differences could be observed. Protein jagged-1 is a
ligand for multiple Notch receptors and involved in the mediation of Notch signaling. It is suggested in literature that the
Notch pathway is involved in the remyelination of MScl lesions. Aberration of normal homeostasis of Vitamin D, of which
approximately 90% is bound to vitamin D-binding protein, has been widely implicated in MScl for some years now. Vitamin
D directly and indirectly regulates the differentiation, activation of CD4+ T-lymphocytes and can prevent the development
of autoimmune processes, and so it may be involved in neuroprotective elements in MScl.
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Introduction
Multiple sclerosis (MScl) can be divided into two major subtypes
based on clinical representation of disease symptoms in the
patients [1]. Between 85–90% of patients can be classified as
having the relapsing remitting (RR) MScl subtype, in which
disease relapses are followed by periods of remission, and 10–15%
of all MScl patients are diagnosed with the primary progressive
(PP) subtype [2]. Even within a single large Dutch MScl pedigree
of 26 patients with similar genetic background, the percentage of
patients with a PP phenotype remained 15% [3].
By definition, in PP patients disease progression is characterized
by a progressive course without relapses or remissions from the
onset of the disease [4]. PP patients tend to have lower
inflammatory lesional activity, for which no immunological or
genetic explanation has been identified yet. The scarce compar-
ative neuropathological studies show a large overlap in lesional
pathology, but indicate less inflammatory activity for PP, with still
substantial axonal damage [5]. The general picture is that relapse
onset and PP forms share substantial characteristics. In other
words, it has remained a challenge to identify the biological
parameters that determine a PP disease course.
Although proteomics analysis of active multiple sclerosis lesions
may be a straightforward approach to study the processes involved
in MScl disease pathways [6], this is very difficult to perform in
living individuals. In most cases the pathology of the disease can
only be investigated in post-mortem material, which quite
frequently represents the end-stage of the disease. The study of
CSF taken during disease appears a good alternative. CSF is in
close contact with the CNS parenchyma and collects the products
of the inflammatory and neurodegenerative processes of MScl
activity.
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that were elevated in MScl patients [7,8]. Additionally, differen-
tially abundant proteins identified by proteomics, such as
apolipoprotein A1 [9] and chromogranin A [10] were validated
by other techniques. Other studies added additional data on
elevated immunoglobulin expression in MScl CSF, as well as
increased levels of apolipoprotein E [11,12]. Yet in all currently
reported proteomics CSF studies of MScl patients either only a
single subtype of MScl patients or a combined group of all
subtypes of MScl was studied, whilst the differences between the
subtypes of MScl remained unexplored. Because RR MScl and PP
MScl are very different in terms of disease course and disease
progression, this also has therapeutic consequences. Hence, there
are probably also differences on a biological and pathological level,
which could, if determined, be very useful for elucidation of the
biology and pathology of both disease types.
In the current study we specifically aimed to differentiate
between the MScl patients and healthy controls and between both
subtypes of MScl by comparing CSF proteins and peptides.
Subsequently, the identified biomarker proteins and peptides were
discussed in relation to the different pathological processes
observed in RR MScl and PP MScl.
Materials and Methods
Ethics Statement
The Medical Ethical Committee, de commissie medisch
ethische vraagstukken, of the Erasmus University Medical Centre
in Rotterdam, The Netherlands, approved the study protocol and
patients gave written consent. The approval numbers for this study
are 200.721/2001/75 and 2006/188.
Patient selection
The CSF samples of MScl patients, divided into two groups, RR
MScl [13] and PP MScl [14], were collected from untreated
patients undergoing routine diagnostic procedures by an experi-
enced neurologist (RQH), and matched for presence or absence of
oligoclonal bands. The healthy control CSF samples were taken
from patients receiving spinal anesthesia prior to non-neurological
minor surgical interventions, such as knee and hip replacements,
groin rupture and Achilles tendon rupture. All samples were
handled in exactly the same way after sampling, using a procedure
that has been previously reported [12]. In brief, immediately after
sampling, the CSF samples were centrifuged to discard cells and
cellular elements and the total protein concentration and albumin
concentrations were determined. The number of oligoclonal bands
and the intrathecal cell count were also reported. The remaining
volume of the samples was aliquoted and stored at 280uC, where
they remained until sample preparation for this study. No extra
freeze-thaw cycles were allowed.
Sample preparation, measurement and analysis
The CSF samples were handled according to the same protocol
for quantitative MALDI-FT-ICR MS measurements we reported
previously [12], which consists of a blinded experiment in which
the samples were digested by trypsin and subsequently measured
by MALDI-FT-ICR (APEX IV Qe 9.6 Tesla MALDI-FT-ICR
mass spectrometer (Bruker Daltonics, USA)). After calibration by
means of omnipresent albumin peaks, an analysis matrix is
generated. A univariate analysis, in which a p-value was
determined for every peak position, was used for statistical
analysis, in which two groups were compared at a time, for a
total of three individual comparisons between the groups. The
differentially abundant peaks (p,0.01) in the comparisons were
considered for identification purposes. The fold increase of every
identified peptide with p,0.01 in the comparisons was determined
to confirm differential abundance between groups. Assessment of
the statistical background, by means of permutation of a series of
50 scramblings of the samples for each comparison, was used to
define a cut-off number for the determination of statistically
significant differences between groups. In this permutation
procedure all samples are randomly assigned a new group
number, scrambling the sample group compositions, prior to
performing the univariate analysis to determine the p-values for
each peak position. By this method the number of peaks that is
assigned a p-value below 0.01 by chance is determined. Iterative
repetition of this procedure allows for a statistically relevant mean
with standard deviation that could be taken as a realistic
background value for this not normally distributed data.
The differentially abundant peptides were identified by nano-
LC-ESI-Orbitrap MS. These measurements were carried out on a
Ultimate 3000 nano LC system (Dionex, Germering, Germany)
online coupled to a hybrid linear ion trap/Orbitrap MS (LTQ
Orbitrap XL; Thermo Fisher Scientific, Germany). Five mL digest
were loaded on to a C18 trap column (C18 PepMap, 300 mmI D
65 mm, 5 mm particle size, 100 A ˚ pore size; Dionex, The
Netherlands) and desalted for 10 minutes using a flow rate of
20 mL/min 0.1% TFA. Then the trap column was switched online
with the analytical column (PepMap C18, 75 mmI D6150 mm,
3 mm particle and 100 A ˚ pore size; Dionex, The Netherlands) and
peptides were eluted with following binary gradient: 0%–25%
solvent B in 120 min and 25%–50% solvent B in further 60
minutes, where solvent A consist of 2% acetonitrile and 0.1%
formic in water and solvent B consists of 80% acetonitrile and
0.08% formic acid in water. Column flow rate was set to 300 nL/
min. For MS detection a data dependent acquisition method was
used: high resolution survey scan from 400–1800 Th. was
performed in the Orbitrap (value of target of automatic gain
control AGC 10
6, resolution 30,000 at 400 m/z; lock mass was set
to 445.120025 u (protonated (Si(CH3)2O)6) [15]). Based on this
survey scan the 5 most intensive ions were consecutively isolated
(AGC target set to 10
4 ions) and fragmented by collision-activated
dissociation (CAD) applying 35% normalized collision energy in
the linear ion trap. After precursors were selected for MS/MS,
they were excluded for further MS/MS spectra for 3 minutes. The
MS/MS identifications were obtained using in the Bioworks 3.2
(peak picking by Extract_msn, default settings) software package
(Thermo Fisher Scientific, Germany), and its’ SEQUEST feature,
using minimum XC scores of 1.8, 2.2 and 3.75 for reliable
identification of single, double and triple charged ions respectively
in the UniProt-database (version 56.0, human taxonomy (20069
entries)). Carboxymethylation of Cysteine (+57.021 u) as fixed and
oxidation of Methionine (+15.996 u) as variable modifications and
tryptic cleavage were considered. The number of allowed missed
cleavages was 2, the mass tolerance for precursor ions was 10 ppm
and for fragment ions 0.5 Da. The cut-off for mass differences with
the theoretical mass of the identified peptides was set at 2 ppm.
Contamination of CSF by serum of plasma is a possible issue in
CSF peptide profiling, because if one or more of the samples is
contaminated by serum or plasma, the comparison of CSF peptide
profiles is inevitably skewed by the higher total protein
concentrations in serum or plasma [16]. To prevent inclusion of
contaminated CSF samples in this study, the CSF samples were
checked for specific blood contamination. If a hemoglobin peptide
could be identified by nanoLC-ESI-Orbitrap (C18 column) with
sufficiently high confidence score or if the mass peak 1274.7255
(part of hemoglobin gamma) has a signal to noise of 4 or higher in
MALDI-FT-ICR measurements, the sample was discarded from
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blood specific protein, apolipoprotein B100 was checked in the
same way as possible blood contamination.
Immuno-assays for validation of differentially abundant
proteins
For two proteins, for which we found differentially abundant
peptides, we performed validation experiments. This was done by
commercially available ELISA (for vitamin D-binding protein) and
by western blot (for protein jagged-1), using a validation cohort of
patients consisting of 10 RR MScl and 10 PP MScl samples. The
samples of the validation cohort were demographically and
clinically comparable to the original cohort of patients (average
EDSS RR MScl group (standard deviation in brackets): 2.5 (0.8),
average EDSS PP MScl group 2.8 (1.0), and the disease duration,
presence/absence of oligoclonal IgG bands and male female ratio
were all similar to the original cohort (no p-values below 0.05)
using a t-test to compare the groups). Additionally we also
measured the original samples using this ELISA and western blot.
For the first protein, vitamin D-binding protein, we performed a
commercially available ELISA (Immundiagnostik, Germany)
according to the manufacturers specifications. For the second
protein that was differentially abundant between the both MScl
types, jagged-1, we performed a two-step western blot using goat
anti-jagged1 antibodies (primary antibody) and anti-goat antibod-
ies (secondary antibody) (Sigma Aldrich, United States). Protein
transfer was checked by Ponceau staining. Quantitative assessment
of the gel bands after photoluminescence was performed using
Image J (freely available at www.rsb.info.nih.gov/ij).
Results
Clinical information
In total 34 CSF samples were used for mass spectrometry
analysis, while twenty of these samples and twenty additional
samples were used for validation experiments. All samples
analyzed by mass spectrometry were tested as being negative for
serum/plasma contamination by MALDI-FT-ICR measurements.
However, in three samples we were able to identify hemoglobin
peptides with sufficiently high XC scores for confident identifica-
tion using nanoLC-ESI-Orbitrap measurements. These three
samples, 2 PP MScl and 1 RR MScl, were subsequently excluded
from further analysis. The analysis matrix, which was used to
profile the differences in peptide profile between the three groups,
consisted therefore of 31 CSF samples (Table 1 and Supplemen-
tary information Samples S1 file).
Peak detection and data analysis
After the MALDI-FT-ICR spectra were loaded into Peptrix
TM
software package, they were each tagged with a group number (1,
2 and 3 for PP MScl, RR MScl and controls respectively).
Calibrating using five omnipresent albumin peaks was followed by
generation of an analysis matrix with the intensity of all peaks of
every sample recorded for all detected peaks (Supplementary
Information Matrix S1 file). Using the Wilcoxon-Mann-Whitney
test to compare the groups pair-wise, the comparison between
both MScl types resulted in 15 peak masses with p-values below
0.01. By scrambling the sample groups the number of background
peaks was determined at 17, so the number of differentially
abundant peptide peaks in the comparison of the two MScl types is
around the level of the number of background peaks, indicating
that the difference between these two groups appears to be
nonexistent or at least at background level. However, the proteins
that were identified with low p-values in this comparison were of
substantial interest in a MScl context.
A total of 43 peptide peaks with a p-value below 0.01 were
observed for the comparison of PP MScl versus the controls. The
comparison of RR MScl versus the controls had 41 peak masses
with p-values lower than 0.01. Seventeen of the peak masses with
p,0.01 were present in both comparisons.
Identification
Identification of the differentially abundant peptides was
performed by measuring all samples using the nanoLC-ESI-
Orbitrap. Due to the prefractionating by nanoLC far more peak
masses and identifications are generated by ESI-Orbitrap than
there are peak masses in the analysis matrix generated by
quantitative MALDI-FT-ICR. Although many of the identified
peptides do not correspond to peak masses in the analysis matrix,
we were able to identify a number of differentially abundant
peptides for all three comparisons (full list, including charge states
and sequence coverage, can be found in the supplementary
material (Supplementary Information Mass Spectrometry S1 file)).
Of the 43 differentially abundant peptide masses that were
observed using MALDI-FT-ICR mass spectrometry in the
comparison of PP MScl versus the controls we were able to
identify 29 peptides (Supplementary Information Table S1). These
peptides included several peptides of Ig gamma-1 and Ig kappa.
Another differentially abundant peptide was identified as a part
apolipoprotein D, which has previously been shown to be elevated
intrathecally in MScl patients [17]. In the comparison of RR MScl
versus controls we were able to identify 24 of the 41 differentially
abundant peptide masses, which, as was the case with the
Table 1. CSF sample information.
PP MScl RR MScl Controls
Number of samples 10 11 10
Protein concentration (g/L) 0.398 (0.118) 0.391 (0.135) 0.386 (0.110)
Albumin concentration (g/L) 0.254 (0.104) 0.228 (0.082) 0.205 (0.090)
Age 48.1 (9.0) 43.9 (14.1) 51.1 (13.7)
EDSS 3.2 (0.8) 2.8 (0.9) -
Disease duration (years) 3.4 (1.3) 2.6 (1.5) -
Male/Female ratio (% females in group) 6/4 (40%) 6/5 (45%) 8/2 (20%)
The concentrations, age, Expanded Disability Status Scale (EDSS) score and disease duration values are averages with standard deviation in brackets. None of the
variables in these tables differed significantly between the groups (all t-tests showed p-values higher than 0.05).
doi:10.1371/journal.pone.0012442.t001
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peptides of Ig gamma-1 and Ig kappa as well as apolipoprotein D
(Supplementary Information Table S2). In fact, of the 24 peptides
identified in this comparison, 14 were also identified in the
comparison of PP MScl versus the controls, indicating that the
differences of the two MScl types compared to the controls are
remarkably similar. Additional proteins with low p-values in the
comparisons of both MScl types with the controls include StAR-
related lipid transfer protein 4 (2.551 fold increase in PP MScl
compared to controls and 2.837 fold increase in RR MScl
compared to controls), LON peptidase N-terminal domain and
RING finger protein (2.847 fold increase in PP MScl and 2.212
fold increase in RR MScl), and ryanodine receptor 1 (2.129 fold
increase in PP MScl and 1.877 fold increase in RR MScl).
PP MScl versus RR MScl
The comparison of PP MScl versus RR MScl showed a limited
number of differentially abundant peptide peaks. Of these peaks 7
were identified, the most notable being protein jagged-1 (Table 2).
This particular protein was over three times less abundant in PP
MScl compared to RR MScl. Another interesting differentially
abundant protein is vitamin D-binding protein, which was not
detected by mass spectrometry in the PP MScl samples but was
detected in the RR MScl samples. Other proteins, such as serine/
threonine kinase NLK and sodium leak channel non-selective
protein were more abundant in PP MScl than in RR MScl,
although for the latter protein the difference was small (1.18 fold
increase).
Because our main interest was focused on the differences
between the two MScl types we selected two differentially
abundant proteins from that comparison for validation purposes
using 10 PP MScl and 10 RR MScl samples measured by mass
spectrometry and an additional 10 PP MScl and 10 RR MScl
samples from independent patients. Validation by ELISA showed
that the concentration of vitamin D-binding protein was
significantly lower (t-test, p,0.05) in the PP MScl group compared
to the RR MScl group in the samples also measured by MALDI-
FT-ICR MS (Table 3). A similar result was observed in the new,
clinically and demographically comparable validation samples
(Table 4) After western blotting, quantitative assessment of the gel
bands showed that protein jagged-1 was indeed less abundant in
PP MScl than in RR MScl. A t-test on the photoluminescence
readout values of the original sample set showed a p-value below
0.05 when comparing the RR and PP MScl samples (Table 3).
The same comparison in the validation samples also showed a p-
value below 0.05), indicating a significant differential abundance of
jagged-1 in the two MScl disease types (Table 4).
In order to place the identified proteins in a biological context,
they were uploaded to the Ingenuity Pathways Analysis service
(Ingenuity Systems) for to network analysis. Six of the seven
differentially abundant proteins were placed in a network relating
to neurological disease (Figure 1).
Discussion
The main finding of this comparative study is the observation
that the proteome profiles of CSF in PP vs RR MScl patients
overlap to a large extent. This is in line with the lack of clear-cut
differences between the two major clinical MScl sub-groups, at
genetic, immunological and neuropathological levels. Interesting-
ly, our approach using sensitive state-of the art mass spectrometry
techniques, led to the identification of a few distinct CSF proteins,
some of them with biological functions that appear of direct
interest for MScl pathology. Two of these proteins were validated
by other techniques as well as in a validation sample set. The lack
of statistical power, due to the low number of biological samples
available for this study, led to a less than ideal statistical analysis,
meaning that the reported p-values may not be directly associated
to disease pathology. However, the reported unvalidated proteins
are of significant biological interest, and among these are several
immunoglobulin proteins, which have been previously reported to
be elevated in CSF of MScl patients [18,19].
The number of peaks with low p-values in the comparison of the
two MScl types is lower than the number of background peaks, so
this is a strong indication that, even though there may be peptides
and proteins that are differentially abundant in the comparison,
overall the difference between the two disease types appears to be
undetectable by means of the univariate analysis. One of the
peptides of protein jagged-1 is over three times less abundant in PP
MScl and also is observed with a lower incidence in this group
(Table 2). Protein jagged-1 is a ligand for multiple Notch receptors
and involved in the mediation of Notch signaling, which influences
neuronal function and development [20]. The Notch signaling
pathway has long been known to influence cell fate in the
developing nervous system. Jagged-1 has been found to be highly
expressed in hypertrophic astrocytes within and around active
MScl plaques lacking remyelination, while, in contrast, there was
negligible jagged-1 expression in remyelinated lesions suggesting
involvement of the Notch pathway in remyelination in MScl [21].
Later, linkage equilibrium screening implicated a number of
Table 2. Differentially abundant peptides and proteins in the comparison of PP MScl versus RR MScl.
Acc.
number Protein
# of
pept. p-value Peptide
Abund.
in PP
MScl
Fold
change
Incidence
in PP MScl
(%)
Incidence
in RR
MScl (%)
P02774 Vitamin D-binding protein 1 0.0092 ELPEHTVKLCDNLSTKNSK Q -0 5 5
P61769 Beta-2-microglobulin 1 0.0014 VEHSDLSFSK q -7 0 0
P78504 Protein jagged-1 1 0.0087 TCMEGWM*GPECNRAICR Q 3.188 30 63
Q8IZF0 Sodium leak channel non-selective protein 1 0.0069 GKSLETLTQDHSNTVRYR q 1.180 80 18
Q8NEB9 Phosphatidylinositol 3-kinase catalytic
subunit type 3
1 0.0015 SALM*PAQLFFK Q -0 7 3
Q9NXT0 Zinc finger protein568 1 0.0071 DQGGHSGERPYECGEYR Q 1.786 80 82
Q9UBE8 Serine/threonine kinase NLK 1 0.0041 YHTCM*CKCCFSTSTGR q -6 0 0
M* denotes oxidation of methionine residue.
doi:10.1371/journal.pone.0012442.t002
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in a large contingent of Europeans [22]. It has also been suggested
that jagged-1 has therapeutic potential in the treatment of CD8
+ T
cell mediated diseases, due to it’s ability to deliver indirect negative
signals into CD8
+ T cells in vivo [23]. Additionally, animal models
have shown that elevated expression of Notch and jagged-1
expression does not appear to be a limiting factor in remyelination,
but the animal model study reports that there were no quantitative
differences in Notch1 expressing cells in slow and rapidly
remyelinating lesions, indicating that Notch–Jagged signaling is
not a rate-limiting determinant of remyelination in rodent models
of demyelination [24]. Additionally immunohistochemistry exper-
iments have shown that constituents of the Notch pathway are
expressed in remyelination in an animal model of T-cell- and
antibody-mediated CNS demyelination [25]. However, network
studies based on the quantitative expression levels of 20 genes in
over one hundred individuals identify jagged-1 as a new
therapeutic target whose differential behavior in the MScl network
was not modified by immunomodulatory therapy, illustrating how
network analysis can predict therapeutic targets for immune
intervention and identifying the immunomodulatory properties of
jagged-1, making it a new therapeutic target for MScl and other
autoimmune diseases [26].
The identified peptide of vitamin D-binding protein is not
observed in any of the PP MScl samples, but small peaks of this
peptide are detected in 6/11 RR MScl samples. Impaired vitamin
D homeostasis has been widely implicated in MScl for some years
now [27–29]. This vitamin directly and indirectly regulates the
differentiation, activation of CD4+ T-lymphocytes and can
prevent the development of autoimmune processes [30,31], and
so it may be involved MScl. Considering that the geographic
incidence of MScl indicates an increase in MScl with a decrease in
sunlight exposure, that vitamin D is produced in the skin by solar
or UV irradiation and that high serum levels of 25-hydroxyvitamin
D have been reported to correlate with a reduced risk of MScl, a
protective role of vitamin D has been suggested [32]. More than
99% of 25-hydroxyvitamin D, the principle circulating metabolite
of vitamin D is bound to proteins, of which approximately 90% is
bound to vitamin D-binding protein [33,34]. Recently, a CSF
proteomics study showed that serum levels of vitamin D-binding
protein were decreased significantly in RR MScl patients
compared to other neurological disorders[35]. While our results
do not indicate a differential abundance difference between the
MScl subtypes and the controls, the two disease types did vary
significantly in CSF levels of vitamin D-binding protein, with RR
MScl showing a higher abundance. Since a neuroprotective
function has been suggested for vitamin D, it may be that in PP
MScl this neuroprotective pathway is at least partially deficient,
resulting in a significantly more disabling disease manifestation.
However, it should not be forgotten that vitamin D-binding
protein has pleiotropic functions, beyond vitamin D metabolism. It
can significantly enhance the chemotactic response to complement
fragment C5a [36], and there are substantial stimulatory effects on
macrophages [37]. In light of the increasingly recognized role of
innate immunity in the progressive phase of MS pathogenesis [38],
vitamin D-binding protein appears an interesting candidate
mediator.
The identification of a peptide of beta-2-microglobulin as
differentially abundant in the comparison between both MScl
disease types is somewhat misleading. Another seven peptides of
this protein were identified among the peak masses in the analysis
matrix that had high p-values in the comparison of PP and RR
MScl, so it is very likely that the low p-value of the peptide of beta-
2-microglobulin reflects high abundant protein variations, sug-
gesting this low p-value is most likely a false positive. In contrast,
the other proteins that are differentially abundant in this
comparison were either identified by the single peptide listed in
Table 2 or by multiple peptides that had low p-values.
The identification of peptides of albumin and serotransferrin
stands out in the tables of the differentially abundant peptides and
Table 3. The results of the validation experiments in the original sample set.
PP MScl RR MScl
Original sample set Average
Standard
deviation Average
Standard
deviation p-value (t-test)
Vitamin D-binding protein concentration in pg/ml (ELISA) 13716 5881 19594 3938 0.017
Protein jagged-1 photoluminescence readout (western blot) 8304 3553 16640 9563 0.019
By ELISA measurement vitamin D binding protein is more abundant in RR MScl than in PP MScl in the original sample set (p=0.017), based on the average (+/2
standard deviation) concentrations in CSF. Protein jagged-1 (western blot) is more abundant in RR MScl than in PP MScl in the original sample set (p=0.019), based on
the averages (+/2 standard deviation) in photoluminescence readout.
doi:10.1371/journal.pone.0012442.t003
Table 4. The results of the validation experiments in the validation sample set.
PP MScl RR MScl
Validation sample set Average
Standard
deviation Average
Standard
deviation p-value (t-test)
Vitamin D-binding protein concentration in pg/ml (ELISA) 15411 6186 23125 8458 0.032
Protein jagged-1 photoluminescence readout (western blot) 9462 3867 19868 14393 0.041
By ELISA measurement vitamin D binding protein is more abundant in RR MScl than in PP MScl in the demographically and clinically comparable validation sample set
(p=0.032), based on the average (+/2 standard deviation) concentrations in CSF. Protein jagged-1 (western blot) is more abundant in RR MScl than in PP MScl in the
validation sample set (p=0.041), based on the averages (+/2 standard deviation) in photoluminescence readout.
doi:10.1371/journal.pone.0012442.t004
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noted that only 2.4% of the identified albumin peptides and 4.8%
of the identified serotransferrin peptides had p-values below 0.01,
which means that the values for the peptides of these two
particular proteins are most likely due to other reasons than large
abundance differences in these two proteins. In comparison, most
of the other differentially abundant proteins that we identified
were found by a small number of peptides with a low p-value or a
single peptide with a low p-value. For these proteins we did not
observe any other peptides with non-significant p-values, with the
exception of bromodomain adjacent to zinc finger domain protein
1A and Rho GTPase-activating protein 18-like. For both of these
proteins another peptide was identified with high p-value,
indicating these proteins were likely not differentially abundant.
The peptides with low p-values of these proteins were also
characterized by a low fold increase, making them less interesting
for independent immunoassay follow-up.
Because of the healthy state of the CSF control group, no
intrathecal inflammatory response was to be expected in this
group. Therefore the very clear difference in immunoglobulin
abundance in the comparison with the both MScl disease types
can be explained. In the two comparisons of both MScl types with
the control group, several proteins are present in both compar-
isons, for example Ig gamma-1 chain C region and apolipoprotein
D. Apolipoproteins have been previously implicated in MScl.
Proteomics studies have shown apolipoprotein E abundances to be
elevated in CSF of MScl patients compared to controls [9,12]. In
the central nervous system apolipoprotein D is a lipocalin that is
mainly expressed in glia, but also in neurons. This protein has
been repeatedly implicated in MScl, and it has been shown that it
Figure 1. Six of the seven differentially abundant proteins (in red) identified in the comparison of the two MScl disease types (PP
and RR) fit into a network related to neurological disease.
doi:10.1371/journal.pone.0012442.g001
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diseases by controlling the level of peroxidated lipids, which
coincides with glial activation in mouse models of encephalitis
[39]. A previous proteomics study showed increased levels of
apolipoprotein D in patients with a clinically isolated syndrome of
demyelination, indicating that abundance levels of this protein are
highest in MScl patients at the time of their first exacerbation
[10,17]. Another potentially interesting protein found to be
differentially elevated in the comparisons of both MScl types with
the controls is ryanodine receptor 1. This receptor is involved in
the maintenance of the calcium-equilibrium in brain tissue. The
release of toxic levels of positively charged calcium ions may, due
to the deleterious effects of excitotoxicity, represent a key
mechanism of axonal degeneration in disorders such as MScl [40].
In conclusion, the CSF peptide profile of the control samples
differed from both MScl types, with, not unexpectedly, proteins
related to immune response showing the highest fold increase in
abundance in the MScl types compared to the controls. Even
though the CSF peptide profiles measured by MALDI-FT-ICR of
PP MScl and RR MScl were quite similar, still a few differences
could be observed, most notably regarding the molecules
confirmed by immunoassay, protein jagged-1 and vitamin D-
binding protein.
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